Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03126630 · OUTCOME

Phase 2 Duration of Response

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma · Source last updated 2026-04-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to 2 years

What was measured

Will be defined as evaluable patients who achieved noted to be a partial response or complete response based Response Evaluation Criteria in Solid Tumors version 1.1 criteria. Will be estimated using the method of Kaplan-Meier. The comparison of duration of response between two treatment arms will be based on the log-rank test. This calculation will start with the date of start of treatment.

Analysis population: Data were not collected and the outcome cannot be reported.

Groups in this outcome

Group I (Pembrolizumab)

Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Upon radiologic documentation of disease progression, patients may cross over to Group II.\> \> Laboratory Biomarker Analysis: Correlative studies\> \> Pembrolizumab: Given IV\> \> Pharmacological Study: Correlative studies

Group II (Anetumab Ravtansine, Pembrolizumab)

Patients receive anetumab ravtansine IV over 1 hour and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 12 months for anetumab ravtansine and up to 24 months for pembrolizumab in the absence of disease progression or unacceptable toxicity.\> \> Anetumab Ravtansine: Given IV\> \> Laboratory Biomarker Analysis: Correlative studies\> \> Pembrolizumab: Given IV\> \> Pharmacological Study: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Group I (Pembrolizumab)0
Group II (Anetumab Ravtansine, Pembrolizumab)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    units
    Participants
description
Will be defined as evaluable patients who achieved noted to be a partial response or complete response based Response Evaluation Criteria in Solid Tumors version 1.1 criteria. Will be estimated using the method of Kaplan-Meier. The comparison of duration of response between two treatment arms will be based on the log-rank test. This calculation will start with the date of start of treatment.
groups
  1. description
    Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Upon radiologic documentation of disease progression, patients may cross over to Group II.\> \> Laboratory Biomarker Analysis: Correlative studies\> \> Pembrolizumab: Given IV\> \> Pharmacological Study: Correlative studies
    id
    OG000
    title
    Group I (Pembrolizumab)
  2. description
    Patients receive anetumab ravtansine IV over 1 hour and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 12 months for anetumab ravtansine and up to 24 months for pembrolizumab in the absence of disease progression or unacceptable toxicity.\> \> Anetumab Ravtansine: Given IV\> \> Laboratory Biomarker Analysis: Correlative studies\> \> Pembrolizumab: Given IV\> \> Pharmacological Study: Correlative studies
    id
    OG001
    title
    Group II (Anetumab Ravtansine, Pembrolizumab)
population Description
Data were not collected and the outcome cannot be reported.
reporting Status
POSTED
time Frame
Up to 2 years
title
Phase 2 Duration of Response
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice